Volume 8, Issue 11

Continuous Alternating Therapies: A Clinical Perspective

In this issue:

Inhaled antibiotics have become the foundation of treating chronic respiratory tract Pseudomonas infection in individuals with cystic fibrosis. But what happens when inhaled monotherapy doesn’t sufficiently manage the symptoms? Which patients are appropriate candidates for treatment with multiple inhaled agents?  Which medications are appropriate for continuous alternating therapy (CAT)?

In this Issue, Dr. Elliott Dasenbrook from the Cleveland Clinic brings the evidence he analyzed in his recent eCysticFibrosis Review Newsletter issue (Vol 8; Issue 10) into the clinic to help guide clinical decision-making.

Learning objectives:

  • Summarize selected patient populations that may benefit from the addition of a second inhaled antibiotic.
  • Describe currently used regimens of continuous alternating therapy with multiple inhaled antibiotics.


Elliott Dasenbrook, MD, MHS
Elliott Dasenbrook, MD, MHS

Director, Cleveland Clinic
Adult Cystic Fibrosis Program
Cleveland, OH

Program Directors:

Peter J. Mogayzel, Jr., MD, PhD

Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins University School of Medicine
Baltimore, MD

Noah Lechtzin, MD, MHA

Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Suzanne Sullivan, RN, BSN

Senior Clinical Nurse
The Johns Hopkins University
Baltimore, MD

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: August 10, 2019
Expiration date: August 9, 2021